74358 Efficacy, Quality-of-Life Improvement, and Predictors of Response to Bimekizumab in Moderate-to-Severe Plaque Psoriasis: A Real-World Prospective Cohort Study
Journal of the American Academy of Dermatology · 2026-07 · 95 (1) · AB194
DOI: 10.1016/j.jaad.2026.04.790 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of the American Academy of Dermatology, 2026-07. Verfasst von Laura Moreno Hernandez und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Hernandez, L. M., Llabrés, A. M., & Taberner, J. E. (2026). 74358 Efficacy, Quality-of-Life Improvement, and Predictors of Response to Bimekizumab in Moderate-to-Severe Plaque Psoriasis: A Real-World Prospective Cohort Study. Journal of the American Academy of Dermatology, 95(1), AB194. https://doi.org/10.1016/j.jaad.2026.04.790
Vancouver
Hernandez LM, Llabrés AM, Taberner JE. 74358 Efficacy, Quality-of-Life Improvement, and Predictors of Response to Bimekizumab in Moderate-to-Severe Plaque Psoriasis: A Real-World Prospective Cohort Study. Journal of the American Academy of Dermatology. 2026;95(1):AB194. doi:10.1016/j.jaad.2026.04.790
BibTeX
@article{Hernandez2026,
author = {Hernandez, Laura Moreno and Llabrés, Andreu Munar and Taberner, Juan Escalas},
title = {74358 Efficacy, Quality-of-Life Improvement, and Predictors of Response to Bimekizumab in Moderate-to-Severe Plaque Psoriasis: A Real-World Prospective Cohort Study},
journal = {Journal of the American Academy of Dermatology},
year = {2026},
volume = {95},
number = {1},
pages = {AB194},
doi = {10.1016/j.jaad.2026.04.790}
}
EUVIMED